{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:37:30Z","timestamp":1783633050480,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T00:00:00Z","timestamp":1543363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.clinthera.2018.10.008","type":"journal-article","created":{"date-parts":[[2018,11,24]],"date-time":"2018-11-24T01:18:33Z","timestamp":1543022313000},"page":"2006-2020.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR"],"prefix":"10.1016","volume":"40","author":[{"given":"David","family":"Cella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Beaumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie","family":"Hudgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Marteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Feuilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Houchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Lapuerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ramage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"H\u00f6rsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H.","family":"Kulke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2018.10.008_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clinthera.2018.10.008_bib2","first-page":"517","article-title":"Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases","volume":"22","author":"Soga","year":"2003","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2018.10.008_bib3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2018.10.008_bib4","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1093\/annonc\/12.suppl_2.S95","article-title":"Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours","volume":"12","author":"Tomassetti","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2018.10.008_bib5","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1210\/er.2003-0014","article-title":"The diagnosis and medical management of advanced neuroendocrine tumors","volume":"25","author":"Kaltsas","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.clinthera.2018.10.008_bib6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000335591","article-title":"ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes","volume":"95","author":"Jensen","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.clinthera.2018.10.008_bib7","first-page":"759","article-title":"Gastrointestinal carcinoid tumors: diagnosis and treatment","volume":"105","author":"Stamatakos","year":"2010","journal-title":"Chirurgia (Buchar)"},{"key":"10.1016\/j.clinthera.2018.10.008_bib8","doi-asserted-by":"crossref","first-page":"R423","DOI":"10.1530\/ERC-16-0200","article-title":"Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours","volume":"23","author":"Dimitriadis","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.clinthera.2018.10.008_bib9","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","volume":"21","author":"Faiss","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.10.008_bib10","first-page":"81","article-title":"Above-label doses of octreotide-LAR in patients with metastatic small intestinal carcinoid tumors","volume":"6","author":"Strosberg","year":"2013","journal-title":"Gastrointest Cancer Res"},{"key":"10.1016\/j.clinthera.2018.10.008_bib11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2011.04693.x","article-title":"Long-term results of treatment of malignant carcinoid syndrome with prolonged release lanreotide (Somatuline Autogel)","volume":"34","author":"Khan","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2018.10.008_bib12","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3748\/wjg.v21.i6.1945","article-title":"Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review","volume":"21","author":"Broder","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinthera.2018.10.008_bib13","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1634\/theoncologist.2014-0120","article-title":"Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study","volume":"19","author":"Strosberg","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.clinthera.2018.10.008_bib14","doi-asserted-by":"crossref","first-page":"e14579","DOI":"10.1200\/jco.2012.30.15_suppl.e14579","article-title":"Above-label doses of octreotide-LAR in patients with metastatic small-intestinal carcinoid tumors","volume":"30","author":"Weber","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.clinthera.2018.10.008_bib15","doi-asserted-by":"crossref","first-page":"vii124","DOI":"10.1093\/annonc\/mds295","article-title":"Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Oberg","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2018.10.008_bib16","series-title":"Neuroendocrine tumors. NCCN Clinical Practice Guidelines in Oncology","author":"National Comprehensive Cancer Network (NCCN)","year":"2017"},{"key":"10.1016\/j.clinthera.2018.10.008_bib17","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2036.2009.04083.x","article-title":"Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR","volume":"30","author":"Toumpanakis","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2018.10.008_bib18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1758834016675803","article-title":"Refractory carcinoid syndrome: a review of treatment options","volume":"9","author":"Riechelmann","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clinthera.2018.10.008_bib19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MPA.0b013e3182328045","article-title":"Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population","volume":"41","author":"Beaumont","year":"2012","journal-title":"Pancreas"},{"key":"10.1016\/j.clinthera.2018.10.008_bib20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10555-015-9573-1","article-title":"Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors","volume":"34","author":"Jimenez-Fonseca","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.clinthera.2018.10.008_bib21","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.dld.2015.12.013","article-title":"Patient-reported outcomes with lanreotide Autogel\/Depot for carcinoid syndrome: an international observational study","volume":"48","author":"Ruszniewski","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.clinthera.2018.10.008_bib22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1477-7525-5-18","article-title":"Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study","volume":"5","author":"Frojd","year":"2007","journal-title":"Health Qual Life Outcome"},{"key":"10.1016\/j.clinthera.2018.10.008_bib23","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.clinthera.2017.09.013","article-title":"Understanding the patient experience with carcinoid syndrome: exit interviews from a randomized, placebo-controlled study of telotristat ethyl","volume":"39","author":"Anthony","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2018.10.008_bib24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12955-016-0527-2","article-title":"Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours","volume":"14","author":"Martini","year":"2016","journal-title":"Health Qual Life Outcome"},{"key":"10.1016\/j.clinthera.2018.10.008_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"For the European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clinthera.2018.10.008_bib26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ijc.1439","article-title":"The EORTC core quality of life questionnaire (QLQ-C30, version 3.0) in terminally ill cancer patients under palliative care: validity and reliability in a Hellenic sample","volume":"94","author":"Kyriaki","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clinthera.2018.10.008_bib27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/bjc.2012.560","article-title":"Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours","volume":"108","author":"Yadegarfar","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2018.10.008_bib28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome","volume":"35","author":"Kulke","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.10.008_bib29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jclinepi.2015.08.007","article-title":"Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust","volume":"69","author":"Giesinger","year":"2016","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.clinthera.2018.10.008_bib30","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European organisation for the research and treatment of cancer quality of life questionnaire core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2018.10.008_bib31","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.clinthera.2016.03.002","article-title":"Patient-reported symptom experiences in patients with carcinoid syndrome after participation in a study of telotristat etiprate: a qualitative interview approach","volume":"38","author":"Gelhorn","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2018.10.008_bib32","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1530\/ERC-14-0173","article-title":"Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide","volume":"21","author":"Kulke","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.clinthera.2018.10.008_bib33","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1210\/jc.2014-2247","article-title":"Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial","volume":"100","author":"Pavel","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2018.10.008_bib34","series-title":"Guidance for Industry Irritable Bowel Syndrome\u2014clinical Evaluation of Products for Treatment","author":"US Food and Drug Administration, Center for Drug Evaluation and Research","year":"2010"},{"key":"10.1016\/j.clinthera.2018.10.008_bib35","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198609113151102","article-title":"Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue","volume":"315","author":"Kvols","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2018.10.008_bib36","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3109\/0284186X.2013.879998","article-title":"European reference values for the quality of life questionnaire EORTC QLQ-C30: results of a German investigation and a summarizing analysis of six European general population normative studies","volume":"53","author":"Hinz","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clinthera.2018.10.008_bib37","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/bmj.322.7298.1357","article-title":"Are quality of life measures patient centred?","volume":"322","author":"Carr","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2018.10.008_bib38","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/bmj.322.7297.1297","article-title":"Using quality of life measures in the clinical setting","volume":"322","author":"Higginson","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2018.10.008_bib39","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/bmj.316.7130.542","article-title":"What are quality of life measurements measuring?","volume":"316","author":"Muldoon","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2018.10.008_bib40","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0277-9536(98)00411-0","article-title":"The disability paradox: high quality of life against all odds","volume":"48","author":"Albrecht","year":"1999","journal-title":"Soc Sci Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818305034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818305034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:49:50Z","timestamp":1758962990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291818305034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0149291818305034"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.10.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}